Zydus Gets EIR For Moraiya Plant From USFDA
The US Food and Drug Administration (USFDA) inspected the facility from 26 July to 5 August, 2022, which came to an end with four observations. The USFDA is responsible for issuing an establishment inspection report (EIR) to an establishment which is the subject of an FDA or FDA contracted inspection, only when the agency finalises to close the inspection
The Zydus Lifesciences said that the US health regulator has sent an establishment inspection report regarding its formulations manufacturing facility in Moraiya near Ahmedabad, on 7 November.
The US Food and Drug Administration (USFDA) inspected the facility from 26 July to 5 August, 2022, which came to an end with four observations.
“The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI),” it added.
The USFDA is responsible for issuing an establishment inspection report (EIR) to an establishment which is the subject of an FDA or FDA contracted inspection, only when the agency finalises to close the inspection.
The shares of Zydus Lifesciences were traded at 2.51 per cent up to Rs 450.85 apiece on the Bombay Stock Exchange.